ZA200401603B - Medicinal compositions containing angiotensin II receptor antagonist. - Google Patents

Medicinal compositions containing angiotensin II receptor antagonist. Download PDF

Info

Publication number: ZA200401603B
Authority: ZA; South Africa
Prior art keywords: composition; substance; treatment; angiotensin; receptor antagonist
Prior art date: 2001-08-28

Application number

ZA200401603A

Other languages

English (en)

Inventor

Toshio Sada

Toshimori Inaba

Original Assignee

Sankyo Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-28

Filing date

2004-02-26

Publication date

2004-10-19

2004-02-26 Application filed by Sankyo Co filed Critical Sankyo Co

2004-10-19 Publication of ZA200401603B publication Critical patent/ZA200401603B/en

Links

239000002333 angiotensin II receptor antagonist Substances 0.000 title claims description 31
229940126317 angiotensin II receptor antagonist Drugs 0.000 title claims description 30
239000000203 mixture Substances 0.000 title claims description 25
150000003839 salts Chemical class 0.000 claims description 49
239000000126 substance Substances 0.000 claims description 47
239000003112 inhibitor Substances 0.000 claims description 32
239000008194 pharmaceutical composition Substances 0.000 claims description 26
230000002265 prevention Effects 0.000 claims description 21
206010003210 Arteriosclerosis Diseases 0.000 claims description 18
208000011775 arteriosclerosis disease Diseases 0.000 claims description 18
-1 K- 10085 Chemical compound 0.000 claims description 17
238000000034 method Methods 0.000 claims description 17
241001465754 Metazoa Species 0.000 claims description 15
239000005480 Olmesartan Substances 0.000 claims description 15
VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 15
229960005117 olmesartan Drugs 0.000 claims description 15
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 14
239000002083 C09CA01 - Losartan Substances 0.000 claims description 12
229960004773 losartan Drugs 0.000 claims description 12
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical group CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 12
239000004480 active ingredient Substances 0.000 claims description 11
208000031225 myocardial ischemia Diseases 0.000 claims description 11
SIHFCVXQGXGQQO-UHFFFAOYSA-N 1-cyclohexyl-1-[[4-[[cyclohexyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]cyclohexyl]methyl]-3-[4-(dimethylamino)phenyl]urea Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)N(C1CCCCC1)CC1CCC(CN(C2CCCCC2)C(=O)NC=2C=CC(=CC=2)N(C)C)CC1 SIHFCVXQGXGQQO-UHFFFAOYSA-N 0.000 claims description 8
239000004072 C09CA03 - Valsartan Substances 0.000 claims description 8
239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 8
WUEHURHTEPWPPO-QZTJIDSGSA-N [4-[(4r,5r)-2-[[[2,6-di(propan-2-yl)phenyl]carbamoylamino]methyl]-4,5-dimethyl-1,3-dioxolan-2-yl]phenyl] dihydrogen phosphate Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC1(C=2C=CC(OP(O)(O)=O)=CC=2)O[C@H](C)[C@@H](C)O1 WUEHURHTEPWPPO-QZTJIDSGSA-N 0.000 claims description 8
229960002198 irbesartan Drugs 0.000 claims description 8
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 8
229960004699 valsartan Drugs 0.000 claims description 8
239000002053 C09CA06 - Candesartan Substances 0.000 claims description 7
239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 7
229960000932 candesartan Drugs 0.000 claims description 7
229960005187 telmisartan Drugs 0.000 claims description 7
XCMUCRXXBCAKCO-UHFFFAOYSA-N 1-benzyl-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-[[3-(1h-pyrazol-5-yl)phenyl]methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(CC=1C=C(C=CC=1)C=1NN=CC=1)CC1=CC=CC=C1 XCMUCRXXBCAKCO-UHFFFAOYSA-N 0.000 claims description 6
TXIIZHHIOHVWJD-UHFFFAOYSA-N 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid Chemical compound CC(C)(C)C(=O)NC1=C(C)C(CC(O)=O)=C(C)C2=C1N(CCCCCCCC)CC2 TXIIZHHIOHVWJD-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
KRMKZDOWCOBWNU-UHFFFAOYSA-N n-[2,6-di(propan-2-yl)phenyl]-2-tetradecylsulfanylacetamide Chemical compound CCCCCCCCCCCCCCSCC(=O)NC1=C(C(C)C)C=CC=C1C(C)C KRMKZDOWCOBWNU-UHFFFAOYSA-N 0.000 claims description 6
XYHAZQCTATWYDN-UHFFFAOYSA-N n-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-2-[4-[2-([1,3]oxazolo[4,5-b]pyridin-2-ylsulfanyl)ethyl]piperazin-1-yl]acetamide Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)CN1CCN(CCSC=2OC3=CC=CN=C3N=2)CC1 XYHAZQCTATWYDN-UHFFFAOYSA-N 0.000 claims description 6
HYEIHNVWTVQZFH-UHFFFAOYSA-N n-(4,6-dimethyl-1-pentyl-2,3-dihydroindol-7-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=C(C)C=C(C)C2=C1N(CCCCC)CC2 HYEIHNVWTVQZFH-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims 4
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 3
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 3
150000001875 compounds Chemical class 0.000 description 28
150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 6
230000000302 ischemic effect Effects 0.000 description 6
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 6
208000014644 Brain disease Diseases 0.000 description 5
206010034567 Peripheral circulatory failure Diseases 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
229940126062 Compound A Drugs 0.000 description 3
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
102100030817 Liver carboxylesterase 1 Human genes 0.000 description 2
101710181187 Liver carboxylesterase 1 Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
150000001483 arginine derivatives Chemical class 0.000 description 2
150000001509 aspartic acid derivatives Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
150000002332 glycine derivatives Chemical class 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
102000008873 Angiotensin II receptor Human genes 0.000 description 1
108050000824 Angiotensin II receptor Proteins 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
235000021068 Western diet Nutrition 0.000 description 1
SFASBVAAXQUPLR-UHFFFAOYSA-N [2,6-di(propan-2-yl)phenyl]-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamic acid Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)N(S(O)(=O)=O)C1=C(C(C)C)C=CC=C1C(C)C SFASBVAAXQUPLR-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
229960004349 candesartan cilexetil Drugs 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
150000005332 diethylamines Chemical class 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000000497 foam cell Anatomy 0.000 description 1
150000002301 glucosamine derivatives Chemical class 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
150000002505 iron Chemical class 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002780 morpholines Chemical class 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
VBFPXFNZWSRGTJ-UHFFFAOYSA-N n-[2,6-di(propan-2-yl)phenyl]hexadecanethioamide Chemical compound CCCCCCCCCCCCCCCC(=S)NC1=C(C(C)C)C=CC=C1C(C)C VBFPXFNZWSRGTJ-UHFFFAOYSA-N 0.000 description 1
229960001199 olmesartan medoxomil Drugs 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200401603A 2001-08-28 2004-02-26 Medicinal compositions containing angiotensin II receptor antagonist. ZA200401603B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2001257435		2001-08-28

Publications (1)

Publication Number	Publication Date
ZA200401603B true ZA200401603B (en)	2004-10-19

Family

ID=19085097

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200401603A ZA200401603B (en)	2001-08-28	2004-02-26	Medicinal compositions containing angiotensin II receptor antagonist.

Country Status (17)

Country	Link
US (1)	US20040198788A1 (pl)
EP (1)	EP1421953A4 (pl)
KR (1)	KR20040032969A (pl)
CN (1)	CN1589154A (pl)
AU (1)	AU2002328569B9 (pl)
BR (1)	BR0212254A (pl)
CA (1)	CA2459017A1 (pl)
CO (1)	CO5560583A2 (pl)
HU (1)	HUP0401696A2 (pl)
IL (1)	IL160438A0 (pl)
MX (1)	MXPA04001878A (pl)
NO (1)	NO20041291L (pl)
NZ (1)	NZ531346A (pl)
PL (1)	PL368843A1 (pl)
RU (1)	RU2004105965A (pl)
WO (1)	WO2003020315A1 (pl)
ZA (1)	ZA200401603B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS20050590A (sr) *	2003-01-31	2007-09-21	Sankyo Company Limited,	Lek za profilaksu i tretman arterioskleroze i hipertenzije
US20090226420A1 (en) *	2005-11-10	2009-09-10	Elizabeth Hauser	Methods of Determining the Risk of Developing Coronary Artery Disease
KR101345876B1 (ko) *	2012-01-31	2013-12-30	인제대학교 산학협력단	피마사르탄을 함유하는 세포, 조직 또는 장기 보존용 조성물
CN112979617A (zh) *	2019-12-17	2021-06-18	中国科学院苏州纳米技术与纳米仿生研究所	一种厄贝沙坦哌嗪盐及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES8705837A1 (es) *	1985-01-10	1987-05-16	Tanabe Seiyaku Co	Un procedimiento para la preparacion de derivados de naftaleno.
US5138069A (en) *	1986-07-11	1992-08-11	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking imidazoles
EP0421441B1 (en) *	1989-10-06	1995-01-25	Fujirebio Inc.	Pantothenic acid derivatives
DE122010000024I1 (de) *	1990-02-19	2010-07-08	Novartis Ag	Acylverbindungen
US5196444A (en) *	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB9025509D0 (en) *	1990-11-23	1991-01-09	Fujisawa Pharmaceutical Co	New amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
KR0169501B1 (ko) *	1990-11-26	1999-03-20	우에하라 아키라	아닐리드 유도체
US5591762A (en) *	1991-02-06	1997-01-07	Dr. Karl Thomae Gmbh	Benzimidazoles useful as angiotensin-11 antagonists
CA2229000C (en) *	1991-02-21	2002-04-09	Sankyo Company, Limited	1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5491172A (en) *	1993-05-14	1996-02-13	Warner-Lambert Company	N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
JP3720395B2 (ja) *	1994-09-20	2005-11-24	京都薬品工業株式会社	新規ヘテロ環誘導体、その製造方法およびその医薬用途
CZ292632B6 (cs) *	1995-10-05	2003-11-12	Kyoto Pharmaceutical Industries, Ltd.	Indolinový, indolový nebo tetrahydrochinolinový derivát a farmaceutický přípravek s jeho obsahem
FR2741619B1 (fr) *	1995-11-28	1998-02-13	Pf Medicament	Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
CA2197364A1 (en) *	1996-02-15	1997-08-16	Toshikazu Suzuki	Phenol compound and process for preparing the same
JPH11228416A (ja) *	1997-10-23	1999-08-24	Takeda Chem Ind Ltd	脂質低下剤
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19916108C1 (de) *	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
ATE480236T1 (de) *	2001-04-25	2010-09-15	Takeda Pharmaceutical	Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans

2002
- 2002-08-27 NZ NZ531346A patent/NZ531346A/en unknown
- 2002-08-27 HU HU0401696A patent/HUP0401696A2/hu unknown
- 2002-08-27 RU RU2004105965/15A patent/RU2004105965A/ru not_active Application Discontinuation
- 2002-08-27 EP EP02762874A patent/EP1421953A4/en not_active Withdrawn
- 2002-08-27 KR KR10-2004-7002806A patent/KR20040032969A/ko not_active Withdrawn
- 2002-08-27 WO PCT/JP2002/008629 patent/WO2003020315A1/ja not_active Ceased
- 2002-08-27 BR BR0212254-5A patent/BR0212254A/pt not_active IP Right Cessation
- 2002-08-27 CN CNA028213645A patent/CN1589154A/zh active Pending
- 2002-08-27 MX MXPA04001878A patent/MXPA04001878A/es unknown
- 2002-08-27 IL IL16043802A patent/IL160438A0/xx unknown
- 2002-08-27 AU AU2002328569A patent/AU2002328569B9/en not_active Ceased
- 2002-08-27 PL PL02368843A patent/PL368843A1/pl not_active Application Discontinuation
- 2002-08-27 CA CA002459017A patent/CA2459017A1/en not_active Abandoned
2004
- 2004-02-26 ZA ZA200401603A patent/ZA200401603B/en unknown
- 2004-02-26 US US10/789,340 patent/US20040198788A1/en not_active Abandoned
- 2004-03-16 CO CO04024652A patent/CO5560583A2/es unknown
- 2004-03-26 NO NO20041291A patent/NO20041291L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1421953A4 (en)	2004-09-15
AU2002328569B9 (en)	2005-10-27
WO2003020315A1 (fr)	2003-03-13
RU2004105965A (ru)	2005-05-10
NO20041291L (no)	2004-05-27
NO20041291D0 (no)	2004-03-26
CA2459017A1 (en)	2003-03-13
CO5560583A2 (es)	2005-09-30
KR20040032969A (ko)	2004-04-17
EP1421953A1 (en)	2004-05-26
MXPA04001878A (es)	2004-06-15
BR0212254A (pt)	2004-10-19
HUP0401696A2 (hu)	2004-11-29
US20040198788A1 (en)	2004-10-07
AU2002328569B2 (en)	2005-09-22
CN1589154A (zh)	2005-03-02
PL368843A1 (pl)	2005-04-04
NZ531346A (en)	2005-10-28
IL160438A0 (en)	2004-07-25

Publication	Publication Date	Title
US9592231B2 (en)	2017-03-14	Therapy for complications of diabetes
US20090221549A1 (en)	2009-09-03	Antihypertensive therapy
US20070196510A1 (en)	2007-08-23	Method for treating resistant hypertension
WO2018071526A1 (en)	2018-04-19	Heterocyclic apelin receptor (apj) agonists and uses thereof
WO2007146900A2 (en)	2007-12-21	Antihypertensive therapy method
EP1314425A1 (en)	2003-05-28	Medicinal compositions for preventing or treating heart failure
BRPI0706863A2 (pt)	2011-04-12	composição de fármacos, uso de uma composição de fármacos e embalagem comercial
KR20150020602A (ko)	2015-02-26	무산증 치료를 위한 그렐린 수용체 효능물질
CN1187050C (zh)	2005-02-02	内皮素拮抗剂和血管紧张肽原酶－血管紧张肽系统抑制剂的联合体系
AU754852B2 (en)	2002-11-28	Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
CN101102755A (zh)	2008-01-09	肾素抑制剂在预防或治疗舒张功能障碍或舒张性心力衰竭中的用途
AU2002328569B9 (en)	2005-10-27	Medicinal compositions containing angiotensin II receptor antagonist
ES2636943T3 (es)	2017-10-10	Beraprost y un inhibidor del sistema renina-angiotensina para usar en el tratamiento de enfermedades renales
HK1061799A (en)	2004-10-08	Medicinal compositions containing angiotensin ii receptor antagonist
JP2009256209A (ja)	2009-11-05	降圧療法
US20080194626A1 (en)	2008-08-14	Antihypertensive drug combination
HK1180956A (en)	2013-11-01	Therapy for complications of diabetes